Literature DB >> 9893058

C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.

C H Chen1, C F Lam, R J Boackle.   

Abstract

Evidence is presented for a new C1 Inhibitor (C1 INH) function. C1 INH was capable of dislodging the entire C1qr2s2 complex from C1-activating substances that bound weakly to the globular heads of C1q. Two different mouse IgG1 monoclonal antibodies with different affinities for C1q globular heads were compared for their complement-activating properties in the presence of normal human serum. As expected the higher affinity monoclonal antibody (Qu) was more effective in binding C1q and causing C1-mediated C4b deposition. Unexpectedly, time responses of C1 (C1q) binding to immobilized 3C7 reached a peak then gradually decreased. However, C1q remained constantly bound to immobilized Qu. These results indicated that after C1 activation in human serum, the entire C1 complex (including C1q) was dislodged from 3C7, but not from immobilized Qu. The addition of purified C1 INH to purified C1, which had bound to immobilized 3C7, resulted in removal of C1 (C1q). Removal of the entire C1qr2s2 did not occur when C1 INH preparations were first neutralized by the addition of purified activated C1s. In summary, it is suggested that C1 INH plays a prominent role in dislodging the entire C1qr2s2 from immunoglobulin preparations which have a low binding affinity for the globular heads of C1q.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893058      PMCID: PMC1364365          DOI: 10.1046/j.1365-2567.1998.00635.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Active disassembly of the first complement component, C-1, by C-1 inactivator.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

2.  Spontaneous activation of serum C1 in vitro. Role of C1 inhibitor.

Authors:  Y Tseng; P H Poon; P Zavodszky; V N Schumaker
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

Review 3.  Activation of the first component of complement.

Authors:  V N Schumaker; P Zavodszky; P H Poon
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

4.  C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.

Authors:  A B Laurell; U Mårtensson; A G Sjöholm
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

5.  A molecular mechanism for the activation of the first component of complement by immune complexes.

Authors:  V N Schumaker; D C Hanson; E Kilchherr; M L Phillips; P H Poon
Journal:  Mol Immunol       Date:  1986-05       Impact factor: 4.407

6.  Molecular characterization of the catalytic domains of human complement serine protease C1r.

Authors:  G J Arlaud; J Gagnon; C L Villiers; M G Colomb
Journal:  Biochemistry       Date:  1986-09-09       Impact factor: 3.162

7.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

8.  Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q.

Authors:  H X Jiang; J N Siegel; H Gewurz
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

9.  Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate.

Authors:  P A Patston; P Gettins; J Beechem; M Schapira
Journal:  Biochemistry       Date:  1991-09-10       Impact factor: 3.162

10.  Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.

Authors:  M Okada; S Utsumi
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

View more
  6 in total

1.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

2.  Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.

Authors:  Hee Young Hwang; Marcus R Duvall; Stephen Tomlinson; Robert J Boackle
Journal:  Mol Immunol       Date:  2008-03-03       Impact factor: 4.407

Review 3.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

4.  Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.

Authors:  Satoru Oji; Eva-Maria Nicolussi; Nathalie Kaufmann; Bleranda Zeka; Kathrin Schanda; Kazuo Fujihara; Zsolt Illes; Charlotte Dahle; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

5.  C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Authors:  Seline A Zwarthoff; Kevin Widmer; Annemarie Kuipers; Jürgen Strasser; Maartje Ruyken; Piet C Aerts; Carla J C de Haas; Deniz Ugurlar; Maurits A den Boer; Gestur Vidarsson; Jos A G van Strijp; Piet Gros; Paul W H I Parren; Kok P M van Kessel; Johannes Preiner; Frank J Beurskens; Janine Schuurman; Daniel Ricklin; Suzan H M Rooijakkers
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

6.  Complement susceptibility in glutamine deprived breast cancer cells.

Authors:  Bradley S Ellison; Mary Kb Zanin; Robert J Boackle
Journal:  Cell Div       Date:  2007-07-11       Impact factor: 5.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.